FDA Inspection 810835 — Chartwell Pharmaceuticals Amityville, LLC

Chartwell Pharmaceuticals Amityville, LLC — FEI 2433247

The FDA completed an inspection of Chartwell Pharmaceuticals Amityville, LLC on December 13, 2012 in Amityville, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 14 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
December 13, 2012
Fiscal Year
2013
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Amityville, NY (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
113321 CFR 211.25(a)GMP Training Frequency
139521 CFR 211.103Actual vs. theoretical yields not determined
194221 CFR 211.180(e)Records reviewed annually
202721 CFR 211.192Investigations of discrepancies, failures
241921 CFR 211.198(a)Complaint Handling Procedure
672821 CFR 314.80(b)Failure to review ADE information
673021 CFR 314.80(b)Failure to develop written procedures
673621 CFR 314.80(c)(1)(ii)Submission of report follow-up
682321 CFR 314.80(c)Failure by applicant to report ADE
682721 CFR 314.80(c)(1)(iv)Failure to identify report content
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports
683221 CFR 314.80(c)(2)Late submission of annual safety reports
684221 CFR 314.80(j)Failure to maintain records
891221 CFR 314.81(b)(2)Timely submission